ArticleFrontiers in oncology2020

The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer.

Chongya Zhai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.